Daiichi Sankyo clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
17 trials changed in the last 30 days: 1 stopped, 8 with notable changes, 8 with minor changes only.
- Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030
- Notable: Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Recruitment opened
- Notable: DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Start date pushed from Sep 18, 2026 to Nov 4, 2026
- Notable: Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) Start date pushed from Oct 1, 2026 to Mar 31, 2027
- Minor: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) Study completion pushed from Aug 31, 2027 to Jun 19, 2029
- Stopped: Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment Trial status changed: Recruiting → Withdrawn
- Notable: DO-01 · Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Primary endpoint(s) modified
- Notable: DS-3939a · Solid Tumors Recruitment opened
- Notable: Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting Primary completion moved earlier from Mar 23, 2032 to Feb 26, 2030
- Notable: Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Primary and study completion dates pushed to Feb 17, 2028
- Minor: Ifinatamab Deruxtecan · Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Trial sites expanded: 132 → 168 locations
- Minor: Raludotatug Deruxtecan (R-DXd) · Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trial sites expanded: 164 → 167 locations
- Minor: Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) Trial sites expanded: 19 → 29 locations
- Minor: DS-1103a Combination Therapy · Advanced Solid Tumors Trial sites expanded: 11 → 15 locations
- Minor: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib · Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer Study completion pushed from Apr 30, 2027 to Dec 14, 2027
- Minor: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Primary completion date changed from estimate of Mar 31, 2026 to Dec 1, 2025
- Minor: DESTINY-Lung06 · Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Trial sites expanded: 242 → 246 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-22 | NCT07890714 A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | Phase 1/2 | Recruiting |
Active trials by phase
| Phase 1 | 16 | |
| Phase 1/2 | 10 | |
| Phase 2 | 6 | |
| Phase 2/3 | 2 | |
| Phase 3 | 18 |
Not charted: 5 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 25
Lung Cancer (18) · Non-Small Cell Lung Cancer (NSCLC) (15) · Breast Cancer (8) · Ovarian Cancer (6) · Bladder Cancer (4) · Gastric Cancer (4) · HER2-Positive Cancer (4) · Leukemia (4) · Acute Myeloid Leukemia (AML) (3) · Endometrial Cancer (3)
Get alerts when Daiichi Sankyo's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.